Martin is a Co-Founder and Chief Executive Officer of Rallybio and has worked in pharmaceutical and biotech R&D for more than 30 years, holding leadership roles at companies including Pfizer, AstraZeneca, and Alexion. He is currently a member of the Board of Directors of Charles River Laboratories, Novo Nordisk, and the 5.01 Acquisition Company. He is also a Senior Advisor at New Leaf Ventures. Martin summarizes the three loves in his life as being family, work, and soccer, but not necessarily in that order.
Martin obtained a First-Class Honours Degree in microbiology from Heriot-Watt University and his Ph.D. in molecular genetics from the University of Edinburgh.
OTHER THINGS WORTH KNOWING ABOUT ME:
When I’m not working, I’m playing soccer, boating, ballroom dancing, training my GSD, and hanging with my grandchildren, Charlie and Sophie.
My favorite sports team is the Heart of Midlothian Football Club.
My greatest non-work accomplishment is still playing competitive soccer at 63.
What is Martin Mackay's net worth?
The estimated net worth of Martin Mackay is at least $40,570.70 as of May 16th, 2016. Dr. Mackay owns 42,706 shares of Rallybio stock worth more than $40,571 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Mackay may own. Learn More about Martin Mackay's net worth.
How do I contact Martin Mackay?
Has Martin Mackay been buying or selling shares of Rallybio?
Martin Mackay has not been actively trading shares of Rallybio within the last three months. Most recently, on Monday, January 10th, Martin Mackay bought 5,504 shares of Rallybio stock. The stock was acquired at an average cost of $10.10 per share, with a total value of $55,590.40. Learn More on Martin Mackay's trading history.
Who are Rallybio's active insiders?
